Table 4 Association between individual SNPs and MM OS, adjusted by stage (Durie-Salmon).

From: Genetically determined telomere length and multiple myeloma risk and outcome

SNP

Gene

Allele

MAFa

EAa

Allelic modelb

Codominant modelc

M/m

HRa

95% CIa

Pvalue

HRHet

95% CI

Pvalue

HRHom

95% CI

Pvalue

rs11125529

ACYP2

C/A

0.11

A

0.90

0.71–1.13

0.369

0.89

0.68–1.16

0.391

0.59

0.37–1.93

0.710

rs6772228

PXK

T/A

0.04

T

1.30

0.89–1.89

0.165

1.18

0.78–1.75

0.426

4.51

1.06–19.17

0.041

rs10936599

TERC

C/T

0.24

C

1.20

1.00–1.43

0.048

1.23

0.98–1.54

0.066

1.34

0.80– 2.23

0.265

rs7675998

NAF1

G/A

0.24

G

1.18

0.98–1.42

0.080

1.11

0.88–1.40

0.374

1.62

0.99–2.63

0.053

rs2736100

TERT

A/C

0.50

C

1.05

0.89–1.22

0.536

1.02

0.77–1.34

0.879

1.10

0.70–1.49

0.545

rs9420907

OBFC1

A/C

0.13

C

0.96

0.78–1.17

0.724

0.95

0.75–1.20

0.690

0.95

0.51–1.85

0.941

rs3027234

CTC1

C/T

0.22

C

1.03

0.86–1.23

0.726

1.00

0.79–1.25

0.993

1.15

0.71–1.83

0.559

rs8105767

ZNF208

A/G

0.28

G

1.01

0.85–1.19

0.913

1.06

0.84–1.32

0.612

0.95

0.62–1.42

0.799

rs412658

ZNF676

C/T

0.35

T

0.98

0.83–1.15

0.847

1.01

0.80–0.25

0.943

0.95

0.66–1.35

0.763

rs6028466

DHX35

G/A

0.07

A

1.15

0.86–1.52

0.350

1.10

0.78–1.54

0.562

1.58

0.58–4.27

0.369

rs755017

ZBTB46

A/G

0.12

G

0.86

0.67–1.09

0.216

0.92

0.70–1.20

0.559

0.44

0.14–1.37

0.158

  1. aMAF minor allele frequency, EA effect allele, allele associated with longer telomere length, HR hazard ratio, 95% CI 95% coefficient interval.
  2. bAllelic model: M vs. m, common allele vs. rare allele.
  3. cCodominant model: Mm vs. MM, heterozygous carriers vs. common homozygous; mm vs. MM, rare homozygous vs. common homozygous.